Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William M Greenberg

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
CNS Drug Reviews|July 14, 2007
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trialsWilliam M Greenberg, Leslie Citrome
Clinical Pharmacokinetics|October 11, 2016
Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published LiteratureWilliam M Greenberg, Leslie Citrome
Psychiatric Rehabilitation Journal|April 27, 2007
Spirituality matters: creating a time and place for hopeNadine Revheim, William M Greenberg
Neurology and Therapy|December 15, 2015
Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical EvidenceWilliam M Greenberg, Leslie Citrome
The American Journal of Orthopsychiatry|October 1, 1982
Preparing for nuclear war: the psychological effectsDavid S Goldman, William M Greenberg
New Jersey Medicine : the Journal of the Medical Society of New Jersey|November 24, 2004
Child and adolescent mental health; June 2004William M Greenberg, Linda G Gochfeld
The Psychiatric Quarterly|April 22, 2010
Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic groupNadine Revheim, William M Greenberg, Leslie Citrome
Journal of Drug Assessment|August 19, 2016
A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorderCarl P Gommoll, William M Greenberg, Changzheng Chen
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|September 6, 2005
A survey of addiction training in child and adolescent psychiatry residency programsMarjorie Waldbaum, Marc Galanter, Helen Dermatis, et al.
International Clinical Psychopharmacology|March 27, 2014
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsAngelo Sambunaris, Carl Gommoll, Changzheng Chen, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
CNS Drug Reviews|July 14, 2007
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trialsWilliam M Greenberg, Leslie Citrome
Clinical Pharmacokinetics|October 11, 2016
Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published LiteratureWilliam M Greenberg, Leslie Citrome
Psychiatric Rehabilitation Journal|April 27, 2007
Spirituality matters: creating a time and place for hopeNadine Revheim, William M Greenberg
Neurology and Therapy|December 15, 2015
Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical EvidenceWilliam M Greenberg, Leslie Citrome
The American Journal of Orthopsychiatry|October 1, 1982
Preparing for nuclear war: the psychological effectsDavid S Goldman, William M Greenberg
New Jersey Medicine : the Journal of the Medical Society of New Jersey|November 24, 2004
Child and adolescent mental health; June 2004William M Greenberg, Linda G Gochfeld
The Psychiatric Quarterly|April 22, 2010
Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic groupNadine Revheim, William M Greenberg, Leslie Citrome
Journal of Drug Assessment|August 19, 2016
A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorderCarl P Gommoll, William M Greenberg, Changzheng Chen
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|September 6, 2005
A survey of addiction training in child and adolescent psychiatry residency programsMarjorie Waldbaum, Marc Galanter, Helen Dermatis, et al.
International Clinical Psychopharmacology|March 27, 2014
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsAngelo Sambunaris, Carl Gommoll, Changzheng Chen, et al.
Pageof 3